首页 | 本学科首页   官方微博 | 高级检索  
检索        

ADV联合LMV治疗LMV耐药慢性乙型肝炎临床疗效
引用本文:薛祖洪,谭正炳,陈曙红.ADV联合LMV治疗LMV耐药慢性乙型肝炎临床疗效[J].中国临床实用医学,2007,3(1):26-28.
作者姓名:薛祖洪  谭正炳  陈曙红
作者单位:江苏省靖江市人民医院感染科,214500;
摘    要:目的 观察ADV联合LMV治疗LMV耐药慢性乙型肝炎临床疗效和安全性.方法 选择YMDD变异株患者68例,随机分为对照组(A组、34例)和治疗组(B组、34例),对照组继续予拉米夫定100 mg/d口服治疗、治疗组联合ADV10 mg/d口服治疗,疗程6月.检测肝、肾功能、HBV DNA,HB-sAg,治疗过程中的病情变化和不良事件的发生率.结果 B组在第6月时,ALT、HBV DNA水平下降明显,与A组比较有显著性差异(P<0.05);A组与B组比较,AL T复常率有显著性统计学差异(P<0.05),HBV DNA转阴率比较无显著性差异(P>0.05),在使用ADV联合LMV治疗过程中,监测肾功能均在正常范围内,未发现明显的毒副作用.结论 ADV联合LMV治疗LMV耐药慢性乙型肝炎患者具有良好的疗效和安全性.

关 键 词:慢性    乙型病毒性肝炎    ADV联合LMV    LMV耐药    

ADV and LMV effect on the Chronic Hepatitis Patients with Hepatitis B Virus LAM-resistant
Abstract:Objective To explore the efficacy and safety of ADV and LMV effect on the chronic hepa-titis patients with Hepatitis B Virus LAM-resistant. Methods The ro11 ed 68 chronic hepatitis patients with Hepatitis B Virus LAM-resistant were randomly divided into two groups:The control group( A group,34 cases) and the treatment group( group B ,34 cases), The patients in control group received lamivudineat therapy at a dose of 100 mg daily;however the patients in treatment group received lamivudineat 100 mg daily and adefovir 10 mg daily therapy, and the course of treatment was 3 months. To detect Liver and Kidney function, HBV DNA, HBsAg, and to observe the change pathogenetic condition and side effect. Results After 3 months, the treatment group's ALT and HBV DNA level decreased, Which were lower than that of group A (P<0.05), The ALT level came down to mormal in the treatment group was biger than that of group A(P<0.05). and HBV DNA level be-tween two groups was inverse. Conclusion ADV and LMV is effective and safe for the chronic hepatitis patients with Hepatitis B Virus LAM-resistant.
Keywords:ChronicViral Hepatitis BADV and LMVLAM-resistant
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号